摘要:目的: 比較咪達普利與培哚普利對原發性高血壓患者的的降壓效果和不良反應。 方法 :將入選的60例1～2級高血壓病患者,隨機分為2組,咪達普利組,每日晨起口服咪達普利(5～10 mg,1次/d),培哚普利組,每日晨起口服培哚普利(4～8 mg,1次/d)。治療4周,觀察2組治療前、后的血壓,記錄不良反應。 結果 :經治療后咪達普利與培哚普利組血壓均明顯下降(Plt;0.05),組間差異無統計學意義(P＞0.05);總不良反應發生率咪達普利組16.8%,培哚普利組20%,而咪達普利組的咳嗽發生率為6.8%,培哚普利組為16.8%。 結論 :咪達普利和培哚普利均能有效降壓,二者降壓效果相似,但咪達普利的咳嗽發生率較低。Abstract: Objective: To compare the antihypertensive efficacy and safety of imidapril versus peridopril in patients with essential hypertension. Methods : Selected 60 patients with mild to moderate essential hypertension, in which divided two groups by random.They were administered imidapril 5～10 mg once daily or and peridopril 4～8 mg once daily for 4 weeks. During the curative period of 4 weeks, the antihypertensive efficacy and adverse reaction were observed. Results :The blood pressure drecreased prominently in both groups after four weeks treament(Plt;0.05), but there was no significant difference in antihypertensive efficacy between the two groups(P＞0.05). The occurrence of the total adverse reaction in imidapril and peridopril groups was 16.8% and 20%, respectively, while the occurrence of the cough in two groups was 6.8% and 16.8%, respectively. Conclusion :Both imidapril and peridopril exert favourable and similar hepotensive effect, however the cough occurrence of imidapril is lower than that of peridopril.
目的總結體液中環狀 RNA 在疾病診斷中作用的研究進展。方法通過閱讀國內外關于體液環狀 RNA 在疾病診斷方面的相關文獻，歸納總結其研究進展。結果環狀 RNA 作為內源性環狀 RNA 分子，因其結構穩定、序列保守、功能多樣、組織細胞特異性等特點，被發現與多種疾病相關。近來研究發現，環狀 RNA 可被分泌至外周血、唾液、尿液、胃液、精漿等體液中，且可穩定存在，并與心血管疾病、神經系統疾病、自身免疫性疾病、各類惡性腫瘤、代謝性疾病等多種疾病相關，具有作為疾病非侵入性檢測生物標志物之重要潛能。結論目前研究發現，體液環狀 RNA 與多種臨床疾病的診斷相關，因此對體液環狀 RNA 與疾病診斷關系的深入研究有助于開發臨床疾病非侵入性診斷標志物，對于疾病的非侵入性診斷具有重要意義。